Table 3.
Psychopharmacological drugs being used at baseline and 12 months later.
| Baseline | 12 months later | |
|---|---|---|
| Antipsychotic treatment, n (%) | ||
| Atypical antipsychotic | 60 (100%) | 60 (100%) |
| Route of antipsychotic, n (%) | ||
| Only oral | 45 (75%) | 38 (63.3%) |
| Only LA IM | 1 (1.7%) | 11 (18.3%) |
| Both | 14 (23.3%) | 11 (18.3%) |
| Type of atypical antipsychotic, n (%) | ||
| Clozapine, oral | 2 (3.3%) | 5 (8.3%) |
| Olanzapine, oral | 14 (23.3%) | 11 (18.3%) |
| Quetiapine, oral | 1 (1.6%) | 9 (15.0%) |
| Risperidone, oral | 27 (45.0%) | 16 (26.7%) |
| Paliperidone, oral/IM | 12 (20.0%) | 18 (30%) |
| Aripiprazole, oral/IM | 17 (28.3%) | 15 (25.0%) |
| Amissulpride, oral | 1 (1.7%) | 1 (1.7%) |
| Chlorpromazine equivalents, mean (SD) dose, mg52,53 | 295.4 (220.6) | 297.4 (236.0) |
| Other drugs, n (%) | ||
| Anticholinergics | 6 (10%) | 17 (28.3%) |
| Antidepressants | 12 (20%) | 21 (35%) |
| Mood stabilizers | 3 (5%) | 4 (6.7%) |
| Benzodiazepines | 3 (5%) | 3 (5%) |
LA: long-acting; IM: intramuscular; SD: standard deviation.